Toggle menu

MAPP2 Study

Start date:
June 2018
End date:
June 2020
Co-ordinated by:
Rachel O'Brien
Main trial site:
Royal Infimary Edinburgh

The development of a new point of care test will detect miR-122 and allow point of care diagnosis of paracetamol toxicity with the aim of improved patient stratification on presentation to hospital and, therefore, improve patient care.

The aim of the study is to establish a biobank of human serum samples from patients with paracetamol overdose to develop and test the performance of our point of care test. This is a prospective, observational cohort study of participants aged 16 years or over presenting to the ED/AMU aiming to recruit 326 participants.

Chief Investigator

Dr James Dear

Consultant in Acute Medicine & Toxicology

Research Team

Rachel O'Brien

Lead Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Claire Cheyne

Research Nurse- Bank Staff

More EMERGE Trials

Molecular and cellular analysis of intracranial tumours

Read more

BRAINED Study

Molecular and cellular analysis of intracranial tumours

MAPP2 Study

The Markers and Paracetamol Poisoning Study 2

The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme

Read more

EMERGE Biobank

Developing a bioresource for all emergency presentations